What a privilege to work with Ilana @IlanaSchlam and team from Dana-Farber alongside Sandra Swain. Here we looked at several TME biomarkers in HER2+ from the B-41 trial.
@FraserNelson No Fraser, DeepMind was a total and utter failure at a structural level
They sold for $600m to the first US company that asked
They should have been the UKs first $1tn company
But the follow on investment wasn’t there and the yanks snapped it up for cheap
if you’re an ai researcher you should really consider working on bio
pretraining is great: data sets are big enough for interesting stuff but not so big you’re spending all your time on weird cluster optimization
post training is in the age of research:
the lab is the only true validation, but it’s expensive so figuring out the limits of what we can do for evals in silico is still very open question
existing stuff kind of works: we have proof of life for the ability of ai to accelerate bio but there is a long way to go
it feels a lot like computer vision after imagenet or nlp after the first transformers started really working
if your idea works, you might get to help improve the human condition. way cooler to talk about at parties than “we pushed benchmark X for chat model Y up by 3 point”
Amplify continues to build!
We're looking for 1 amazing person to drive our Bio platform effort. Reach out if you:
- Are unreasonably excited about AI x Bio
- Would build relationships with brilliant scientists, developers, and execs - even if it wasn't your job
- Have a talent for building community, content, and connection